|Articles|April 1, 2001

Updates

Closing the gaps in child-restraint laws, Cause of death: SIDS, or murder? When children kill, Babies First campaign. Eye on Washington

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak | Image Credit: © Tada Images - stock.adobe.com.

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak

ByMorgan Ebert, Executive Editor

August 27th 2026

Treatment choice for pediatric anxiety may depend on preference and access

Treatment choice for pediatric anxiety may depend on preference and access

ByBradley Peterson, MD

August 27th 2026

What pediatricians should know for the upcoming respiratory virus season

What pediatricians should know for the upcoming respiratory virus season

ByLori Handy, MD, MSCE

August 27th 2026

CBT and fluoxetine show comparable improvement for pediatric anxiety

CBT and fluoxetine show comparable improvement for pediatric anxiety

ByBradley Peterson, MD

August 26th 2026

FDA approves dolutegravir dispersible tablets for HIV-infected newborns

FDA approves dolutegravir dispersible tablets for HIV-infected newborns

ByMorgan Ebert, Executive Editor

August 26th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA authorizes Avulux light-filtering lenses for migraine-associated light sensitivity in patients 12 and older

New multisociety position paper details hospital strategies to close gaps in sepsis care

FDA approves dolutegravir dispersible tablets for HIV-infected newborns

What pediatricians should know for the upcoming respiratory virus season

Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children